The domestic Continuous Glucose Monitoring (CGI) device development project, which will be carried out under the leadership of the Biotechnology Research Group of the Vice Presidency of Climate and Life Sciences of TÜBİTAK Marmara Research Center (MAM) and in partnership with Primewize Teknoloji A.Ş., was officially launched with a signing ceremony.
The ceremony held at TÜBİTAK MAM was attended by Prof. Dr. Burcu Özsoy, President of TÜBİTAK MAM, Assoc. Prof. Dr. Hilal Yazıcı Malkoçoğlu, Biotechnology Research Group Leader, Dr. Müfide Karahasanoğlu, Project Manager Resul Turgay and Seçil Selçuk Güven, Senior Lead Specialist. Primewize Teknoloji A.Ş. was represented by Mehmet Halit Calayır, Chairman of the Board of Directors, and Ömer Öztürk and Tarık Öztürk, Board Members.
At the signing ceremony, a licensing and partnership agreement was signed between the parties and it was announced that R&D studies were initiated to develop a wearable and biocompatible SGI device placed on the skin that will enable individuals with diabetes to monitor their glucose levels continuously, with high accuracy and in a user-friendly way.
The domestic SGI device to be developed is aimed to reduce Turkey's foreign dependence in this field after the commercialization process and to make a strategic contribution to the domestic production capacity in health technologies.
The project aims to strengthen Turkey's position in global competition in health technologies and increase access to innovative solutions in diabetes management.
